Phan Thanh Thuy, Vu Van Giap, Tuyet-Lan Le-Thi, Nguyen Viet Nhung, Ngo Quy Chau
Hanoi Medical University, Hanoi, Vietnam.
Respiratory Center, Bach Mai Hospital, Hanoi, Vietnam.
Health Serv Insights. 2023 Jun 2;16:11786329231177545. doi: 10.1177/11786329231177545. eCollection 2023.
Chronic obstructive pulmonary disease (COPD) out-patient clinic is for stable patients but it requires patient's adherence to medicine and medical checkups. Our study aimed to assess COPD out-patient clinics management efficacy with respect to medication adherence and treatment costs at 3 out-patient clinics. Data were collected through 514 patient interviews and from medical records for statistical analysis. The most common comorbidity was hypertension (28.8%), and 52.9% of patients had experienced exacerbations in the past year requiring 75.7% of them to be hospitalized. According to the Morisky scale, 78.8% had high adherence and 82.9% were using inhaled corticosteroids regimens. The mean cost per year among different cohorts varied, with the out-patient cohort at $305.93, the acute exacerbations of COPD non-hospital cohort at $247.39, the standard admission cohort at $1275.3, and the emergency department cohort at $2132.5. Patients with low medication adherence had significantly lower annual costs ($238.25 vs $325.04, = .001). In Vietnam, economic constraints have made Inhaled corticosteroids/ Long-acting β-2 agonists the main mode of treatment. However, the exclusion of Long-acting β-2 agonists/Long-acting anti-muscarinic antagonists drugs from health insurance coverage poses a challenge to Global Initiative for Chronic Obstructive Lung Disease-based prescription practices and increases the importance of monitoring medication adherence, particularly in patients with higher COPD Assessment Test scores.
慢性阻塞性肺疾病(COPD)门诊是针对病情稳定的患者,但这需要患者坚持服药并接受医学检查。我们的研究旨在评估3家门诊在药物依从性和治疗费用方面的慢性阻塞性肺疾病门诊管理效果。通过对514名患者的访谈和病历收集数据进行统计分析。最常见的合并症是高血压(28.8%),52.9%的患者在过去一年中经历过病情加重,其中75.7%的患者需要住院治疗。根据莫利斯基量表,78.8%的患者依从性高,82.9%的患者使用吸入性糖皮质激素治疗方案。不同队列的年平均费用各不相同,门诊队列每年305.93美元,慢性阻塞性肺疾病急性加重非住院队列每年247.39美元,标准住院队列每年1275.3美元,急诊科队列每年2132.5美元。药物依从性低的患者年费用显著较低(238.25美元对325.04美元,P = 0.001)。在越南,经济限制使得吸入性糖皮质激素/长效β2受体激动剂成为主要治疗方式。然而,长效β2受体激动剂/长效抗毒蕈碱拮抗剂药物被排除在医疗保险覆盖范围之外,这对基于慢性阻塞性肺疾病全球倡议的处方实践构成了挑战,并增加了监测药物依从性的重要性,特别是在慢性阻塞性肺疾病评估测试得分较高的患者中。